ATE481103T1 - Derivate von 2-(8,9-dioxo-2,6- diazabicyclo(5.2.0)non-1(7)-en-2- yl)alkylphosphonsäure und deren verwendung als n- methyl-d-aspartat- (nmda-) rezeptorantagonisten - Google Patents

Derivate von 2-(8,9-dioxo-2,6- diazabicyclo(5.2.0)non-1(7)-en-2- yl)alkylphosphonsäure und deren verwendung als n- methyl-d-aspartat- (nmda-) rezeptorantagonisten

Info

Publication number
ATE481103T1
ATE481103T1 AT04759168T AT04759168T ATE481103T1 AT E481103 T1 ATE481103 T1 AT E481103T1 AT 04759168 T AT04759168 T AT 04759168T AT 04759168 T AT04759168 T AT 04759168T AT E481103 T1 ATE481103 T1 AT E481103T1
Authority
AT
Austria
Prior art keywords
alkylphosphoic
nmda
dioxo
diazabicyclo
aspartate
Prior art date
Application number
AT04759168T
Other languages
German (de)
English (en)
Inventor
Reinhardt Baudy
John Butera
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33299828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE481103(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Application granted granted Critical
Publication of ATE481103T1 publication Critical patent/ATE481103T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04759168T 2003-04-09 2004-04-07 Derivate von 2-(8,9-dioxo-2,6- diazabicyclo(5.2.0)non-1(7)-en-2- yl)alkylphosphonsäure und deren verwendung als n- methyl-d-aspartat- (nmda-) rezeptorantagonisten ATE481103T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46149003P 2003-04-09 2003-04-09
PCT/US2004/010596 WO2004092189A1 (en) 2003-04-09 2004-04-07 Derivatives of 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkyl phosphonic acid and their use as n-methyl-d-aspartate (nmda) recetor antagonists

Publications (1)

Publication Number Publication Date
ATE481103T1 true ATE481103T1 (de) 2010-10-15

Family

ID=33299828

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04759168T ATE481103T1 (de) 2003-04-09 2004-04-07 Derivate von 2-(8,9-dioxo-2,6- diazabicyclo(5.2.0)non-1(7)-en-2- yl)alkylphosphonsäure und deren verwendung als n- methyl-d-aspartat- (nmda-) rezeptorantagonisten

Country Status (19)

Country Link
US (2) US7253153B2 (https=)
EP (1) EP1611144B1 (https=)
JP (1) JP4621659B2 (https=)
CN (1) CN1863810B (https=)
AR (1) AR044013A1 (https=)
AT (1) ATE481103T1 (https=)
AU (1) AU2004230895B2 (https=)
BR (1) BRPI0409255A (https=)
CA (1) CA2521313A1 (https=)
CL (1) CL2004000769A1 (https=)
CY (1) CY1110863T1 (https=)
DE (1) DE602004029146D1 (https=)
DK (1) DK1611144T3 (https=)
ES (1) ES2350449T3 (https=)
MX (1) MXPA05010760A (https=)
PL (1) PL1611144T3 (https=)
PT (1) PT1611144E (https=)
TW (1) TWI349674B (https=)
WO (1) WO2004092189A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7687080B2 (en) * 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
GT200400213A (es) * 2003-10-22 2007-09-05 Metodos para la preparacion del acido {2-[(8,9)-dioxo-2,6-diaza-biciclo[5.2.0]-non-1(7)-en-2-il]etil} fosfonico y esteres del mismo
MX2007004138A (es) * 2004-10-08 2007-06-15 Wyeth Corp Derivados de acido [2-(8,9-dioxo-2,6-diazabiciclo [5.2.0] non-1(7)-en-2-il-) alquil] fosfonico y metodos de preparacionde los mismos.
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
EP2195031A1 (en) * 2007-08-27 2010-06-16 Wyeth a Corporation of the State of Delaware Compositions and methods employing nmda antagonists for achieving an anesthetic-sparing effect
ES2388958T3 (es) 2007-11-29 2012-10-22 Actelion Pharmaceuticals Ltd. Derivados de acido fosfonico y su uso como antagonista del receptor P2Y12
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
EP2334176A4 (en) * 2008-09-27 2012-05-02 Taraxos Inc TOPICAL FORMULATIONS FOR THE TREATMENT OF NERVE DISEASES
KR101694563B1 (ko) 2009-04-08 2017-01-09 액테리온 파마슈티칼 리미티드 Ａｄｐ 수용체 길항제로서 6-(3-아자-비시클로〔3.1.0〕헥스-3-일)-2-페닐-피리미딘
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
WO2012137225A1 (en) * 2011-04-08 2012-10-11 Sphaera Pharma Pvt. Ltd Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds
HUE057772T2 (hu) 2016-09-22 2022-06-28 Idorsia Pharmaceuticals Ltd Kristályos formák
US11179390B2 (en) 2017-03-15 2021-11-23 Idorsia Pharmaceuticals Ltd Subcutaneous administration of a P2Y12 receptor antagonist
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
US10902020B2 (en) * 2018-06-08 2021-01-26 International Business Machines Corporation Multiple cache processing of streaming data

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624898A (en) * 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
US5168103A (en) * 1991-01-22 1992-12-01 American Home Products Corporation [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
US5124319A (en) * 1991-10-11 1992-06-23 American Home Products Corporation Benzimidazole phosphono-amino acids
DK124393D0 (da) 1993-11-03 1993-11-03 Lundbeck & Co As H Compounds
TW427904B (en) 1995-12-07 2001-04-01 American Home Prod Neuroprotective agents
UA52698C2 (uk) 1996-10-04 2003-01-15 Х. Луннбек А/С Похідні (3-алкоксіізоксазол-4-іл)заміщеної 2-амінокарбонової кислоти та їх сірковмісні аналоги, фармацевтична композиція на їх основі
US5990307A (en) * 1997-08-01 1999-11-23 American Home Products Corporation Process for the preparation of [2-((8.9)-Dioxo-2,6-Diazabicyclo [5.2.0]-Non-1(7)-en-2yl) Ethyl]Phosphonic acid
CA2297411C (en) 1997-08-01 2008-12-02 American Home Products Corporation Process for the preparation of [2-((8,9)- dioxo-2,6-diazabicyclo [5.2.0]-non-1(7)-en-2-yl)-ethyl] phosphonic acid
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US6225343B1 (en) * 1999-06-16 2001-05-01 Nastech Pharmaceutical Company, Inc. Compositions and methods comprising morphine gluconate
UA78529C2 (en) * 2001-10-10 2007-04-10 Wyeth Corp Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain
US20040082543A1 (en) 2002-10-29 2004-04-29 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
EP1622625A1 (en) * 2003-04-09 2006-02-08 Wyeth Pharmaceutical compositions for intranasal administration of [2-(8,9-dioxo-2,6-diazabicyclo [5.2.o] non-1 (7)-en-2-yl )alkyl] phosphonic acid and derivatives and methods of use thereof
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
US20050142192A1 (en) * 2003-10-15 2005-06-30 Wyeth Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives

Also Published As

Publication number Publication date
AU2004230895A1 (en) 2004-10-28
CL2004000769A1 (es) 2005-02-04
US20070225257A1 (en) 2007-09-27
CN1863810B (zh) 2010-12-01
PL1611144T3 (pl) 2011-03-31
TW200504085A (en) 2005-02-01
EP1611144B1 (en) 2010-09-15
MXPA05010760A (es) 2005-12-12
JP4621659B2 (ja) 2011-01-26
TWI349674B (en) 2011-10-01
DE602004029146D1 (de) 2010-10-28
EP1611144A1 (en) 2006-01-04
BRPI0409255A (pt) 2006-03-28
CA2521313A1 (en) 2004-10-28
AU2004230895B2 (en) 2010-09-09
CN1863810A (zh) 2006-11-15
PT1611144E (pt) 2010-11-12
WO2004092189A1 (en) 2004-10-28
AR044013A1 (es) 2005-08-24
DK1611144T3 (da) 2010-11-22
CY1110863T1 (el) 2015-06-10
US20050004080A1 (en) 2005-01-06
US7879825B2 (en) 2011-02-01
JP2006523694A (ja) 2006-10-19
US7253153B2 (en) 2007-08-07
ES2350449T3 (es) 2011-01-24

Similar Documents

Publication Publication Date Title
ATE481103T1 (de) Derivate von 2-(8,9-dioxo-2,6- diazabicyclo(5.2.0)non-1(7)-en-2- yl)alkylphosphonsäure und deren verwendung als n- methyl-d-aspartat- (nmda-) rezeptorantagonisten
DE60325493D1 (de) Substituierte 1,4-dipiperidin-4-yl-piperazinderivate und deren verwendung als neurokininantagonisten
ATE532772T1 (de) Piperazinderivate und deren verwendung als therapeutische mittel
ATE442348T1 (de) Amino substituierte phenylessigsäuren sowie deren derivate, deren herstellung und deren verwendung als cyclooxygenase 2 (cox-2) inhibitoren
CH1175401H1 (de) Piperazin Derivate verwendbar als CCR5 Antagonisten
DE602005023963D1 (de) Weitere heteropolycyclische verbindungen und deren verwendung als antagonisten des metabotropen glutamatrezeptors
ATE496884T1 (de) Sulphonylaminoessigsaeure derivate und deren verwendung als orexin rezeptor antagoniste
CY1105621T1 (el) Νεα ετεροκυκλικα παραγωγα φθορογλυκοζιτου, φαρμακα που περιεχουν τις ενωσεις αυτες και η χρηση τους
DE60012223D1 (de) Harnstoffderivate wirksam als muscarinrezeptor-antagonisten
BR9911575A (pt) Heterocìclicos de alquilsulfóxido 4-benzil piperidina e seu uso como antagonistas receptores de nmda seletivas do subtipo
ATE349434T1 (de) Lactamderivaten zur verwendung als humane 11cby rezeptorantagonisten
DE50312747D1 (de) Neue xanthinderivate, deren herstellung und deren verwendung als arzneimittel
ATE419849T1 (de) Diaminotriazole derivate und deren verwendung als protein kinase inhibitoren
DE60336266D1 (de) Substituierte 1-piperidin-4-yl-pyrrolidin-3-yl-piperazinderivate und deren verwendung als neurokinin antagonisten
CY1105879T1 (el) Αζαδικυκλο παραγωγα ως ανταγωνιστες μουσκαρινικου υποδοχεα
DE60303440D1 (de) Benzoxazinonderivate, deren herstellung und deren verwendung als medikamente
DE602005011593D1 (de) Substituierte diazaspiroä5.5üundecanderivate und deren verwendung als neurokininantagonisten
ATE518834T1 (de) 2,3,4,9-tetrahydro-1h-carbazol-derivative als crth2-rezeptorantagonisten
DE50305374D1 (de) Neue prodrugs von 1-methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carbonsäure-(n -2-pyridil-n-2-hydroxycarbonylethyl)-amid, ihre herstellung und ihre verwendung als arzneimittel
ATE343582T1 (de) Derivate von (6, 7-dihydro -5h-imidazo(1,2 - a)imidazol -3 -sulfonylamino)-propionamid und deren verwendung als inhibitoren der interaktion von cams und leukointreginen
DE60305026D1 (de) 3,4-dihydrochinolin-2(1h)-on verbindungen als nr2b rezeptor antagonisten
DE60327375D1 (de) Arylindenopyridin- und arylindenopyrimidinverbindungen und ihre verwendung als adenosin-a2a-rezeptor antagonisten
ATE384049T1 (de) Therapeutische heterocyclen als bradykinin b2 rezeptor antagonisten
DE60120711D1 (de) Arylethene-sulfonamid derivate, deren herstellung und deren verwendung als endothelin-antagonisten
ATE401333T1 (de) 1-oxa-3,9-diazaspiroc5.5üundecan-2-onderivate und deren verwendung als antagonisten des neurokininrezeptors

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1611144

Country of ref document: EP